Conference report - Phase III VISIBLE 2 study investigating subcutaneous vedolizumab for Crohn’s disease meets primary outcome for clinical remission

The results show that at week 52, significantly more patients on vedolizumab SC compared to placebo were in clinical remission (48.0% [n=132/275] vs. 34.3% [n=46/134] respectively; [p=0.008]), meeting the study’s primary endpoint.

SPS commentary:

Vedolizumab is currently only licensed for intravenous administration.